Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SDCBP | O00560 | 7/20 | 0.55 |
| ▸ | SDC2 | P34741 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1500260 | 0.85 | SDCBP (0.58) | SDCBPSDC2MEN1KMT2A | |
| SCHEMBL1500196 | 0.83 | SDCBP (0.57) | SDCBPSDC2 | |
| SCHEMBL2177896 | 0.80 | SDCBP (0.65) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL21929834 | 0.80 | SDCBP (0.46) | SDCBPSDC2MEN1KMT2APRMT5 | |
| SCHEMBL2177628 | 0.80 | SDCBP (0.61) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL1500322 | 0.78 | SDCBP (0.59) | SDCBPSDC2DPP8DPP9DPP7 | |
| SCHEMBL21612919 | 0.78 | SDCBP (0.76) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL2181199 | 0.78 | SDCBP (0.76) | SDCBPSDC2ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL1500359 | 0.77 | SDCBP (0.52) | SDCBPSDC2 | |
| SCHEMBL21929926 | 0.77 | SDCBP (0.52) | SDCBPSDC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266892-B2 | Fused pyrazoles as FGFR inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140171405-A1 | Fused Pyrazoles as FGFR Inhibitors | INCYTE CORPORATION (US) | 2014-06-19 | — | — | US | disclosed |
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-7902369-B2 | Diaryl-substituted five-membered heterocycle derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | MSD K.K. (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1726585-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171405-A1 | Fused Pyrazoles as FGFR Inhibitors | FGFR1, FGFR3, FGFR2 | SDCBP 2933/4885SDC2 3021/4885MEN1 4042/4885 |
| US-20110160208-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | OPRK1, GRM1, GRIK1 | SDCBP 2018/4885SDC2 2553/4885MEN1 4608/4885 |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | OPRK1, OPRL1, GRM1 | SDCBP 1614/4885SDC2 2393/4885MEN1 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.